Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment
Beom-Jun Kim(Baylor College of Medicine), Eric C. Chang(Baylor College of Medicine), Dan Ye(Southwestern Medical Center), Purba Singh(Baylor College of Medicine), Matthew V. Holt(Baylor College of Medicine), Ariella B. Hanker(Southwestern Medical Center), Meenakshi Anurag(Baylor College of Medicine), Arun Sreekumar(University of Michigan–Ann Arbor), Hilda Kennedy(Baylor College of Medicine), George Miles(Baylor College of Medicine), Nada Mohamed(Baylor Scott & White Health), Diana Fandino(Baylor College of Medicine), Bora Lim(Baylor College of Medicine), Jonathan T. Lei(Baylor College of Medicine), Matthew J. Ellis(Baylor College of Medicine), Jaya Ruth Asirvatham(Baylor Scott & White Medical Center - Temple), Yongchao Dou(Baylor College of Medicine), Emmanuel Bikorimana(Southwestern Medical Center), Susan G. Hilsenbeck(Baylor College of Medicine), Yunguan Wang(Southwestern Medical Center), María del Rosario Chica-Parrado(Southwestern Medical Center), Anran Chen(Baylor College of Medicine), Bing Zhang(Baylor College of Medicine), Jianheng Peng(Baylor College of Medicine)
Cited by 8
Related Papers
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
|Journal of Clinical Oncology|2001|1.1k
How many human proteoforms are there?
|Nature Chemical Biology|2018|942